Menu Search
Equities

ATAI Life Sciences NV

  • Add to watchlist
  • Add to portfolio
  • Add an alert
9VC:BER

ATAI Life Sciences NV

Actions
  • Price (EUR)2.25
  • Today's Change-0.02 / -0.88%
  • Shares traded30.00
  • 1 Year change+70.69%
  • Beta1.4487
Data delayed at least 15 minutes, as of Jul 14 2025 07:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. The Company focused on developing treatments for mental health disorders. The Company's pipeline includes psychedelic and non-psychedelic compounds targeting depression, anxiety, and other unmet needs in psychiatry.

  • Revenue in USD (TTM)1.87m
  • Net income in USD-148.99m
  • Incorporated2020
  • Employees54.00
  • Location
    ATAI Life Sciences NVWallstrasse 16Berlin 10179GermanyDEU
  • Phone+49 8 921539035
  • Fax+49 89 215390351
  • Websitehttps://atai.life/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		9VCX:GER since
announced		Transaction
value
Beckley Psytech LtdAnnounced02 Jun 202502 Jun 2025Announced12.75%--
Data delayed at least 15 minutes, as of Jul 14 2025 16:35 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.